바로가기메뉴

본문 바로가기 주메뉴 바로가기
 
 

logo

  • ENGLISH
  • P-ISSN1226-6396
  • E-ISSN2234-4942
  • KCI

疏風順氣元이 mouse의 NMu2Li 간세포와 C2C12 골격근세포에서 PPARs 조절의 분자기전에 미치는 영향

A Molecular Study of Sopungsungi-won(Shufengshunqiyuan) about Regulation of PPARs in Mouse NMu2Li Liver Cells and C2C12 Skeletal Muscle Myogenic Progenital Cells

동의신경정신과학회지 / Journal of Oriental Neuropsychiatry, (P)1226-6396; (E)2234-4942
2009, v.20 no.1, pp.147-164
오영진 (동의대학교)
신순식 (동의대학교)
윤미정 (목원대학교)
김보경 (동의대학교)

초록

본 논문은 소풍순기원(疏風順氣元)이 mouse의 NMu2Li 간세포와 C2C12 골격근세포에서 PPARs 조절의 분자기전에 미치는 영향에 관한 것으로, 주요 내용은 대사성 증후군 치료를 위한 소풍순기원 (SSEx1, SSEx2)의 PPAR 및 미토콘드리아 MCAD, VLCAD mRNA 발현 조절의 분자학적 기전을 조사하였다. 1. SSEx1은 0.1 ${\mu}$g/ml (p${\mu}$g/ml (p<0.05)의 농도에서, SSEx2는 0.1 ${\mu}$g/ml (p${\mu}$g/ml (p<0.05)의 농도에서 NMu2Li 간세포의 PPAR${\alpha}$ 리포터 유전자 활성의 발현을 증가시켰다. SSEx1은 1 ${\mu}$g/ml (p${\mu}$g/ml (p${\alpha}$ 리포터 유전자 활성을 증가시켰다. SSEx1 및 SSEx2는 C2C12 골격근 세포의 PPAR${\alpha}$ 리포터 유전자 활성의 발현을 상당히 변화시키지 않았다. SSEx1은 NMu2Li 간세포주에서 미토콘드리아 MCAD mRNA 발현 (p<0.05)을 증가시켰다. SSEx1과 SSEx2 모두는 C2C12 골격근 세포에서 미토콘드리아 MCAD mRNA 발현 (p<0.05)을 증가시켰다. 위 결과로부터 PPAR의 분자학적 기전은 PPAR${\delta}$ 리포터 유전자 활성보다는 PPAR${\alpha}$ 의 활성에 기인하고, 그 총 RNA는 VLCAD mRNA 발현보다는 미토콘드리아 MCAD 조절에 기인한다는 내용이다.

keywords
Sopungsungi-won(Shufengshunqiyuan) (SSEx1, SSEx2), PPARα, PPARδ, MCAD, VLCAD, metabolic syndrome

Abstract

Objectives : We investigated the effects of Sopungsungi-won(Shufengshunqiyuan) (SSEx1, SSEx2) to treat the metabolic syndrome by the molecular mechanism of regulation of PPAR and modulation of mitochondrial MCAD, VLCAD mRNA expression. Methods : Mouse NMu2Li liver cells and C2C12 skeletal muscle myogenic progenital cells were transiently transfected with expression plasmids for PPAR(PPARα, PPARδ), a luciferase reporter gene construct containing 3 copies of the PPRE from the rat acyl-CoA oxidase gene and β-galactosidase gene. Cells were treated with several concentrated kinds of SSEx1, SSEx2 at the initial time of culture and analyzed PPARα, PPARδ reporter gene activity using spectrophotometer (405 nm). Total RNA was extracted from SSEx1, SSEx2 and measured mRNA levels of mitochondrial MCAD, VLCAD. Representative RT-PCR bands are shown. Results : 1. SSEx1 increased the expression of PPARα reporter gene activities at 0.1 μg/ml (p<0.01) and 10 μg/ml (p<0.05), SSEx2 at 0.1 μg/ml (p<0.01) and 1 μg/ml (p<0.05) significantly in NMu2Li liver cell lines. 2. SSEx1 increased the expression of PPARα reporter gene activities at 1 μg/ml (p<0.01), SSEx2 at 0.1 μg/ml (p<0.01) significantly in C2C12 skeletal muscle cells. 3. SSEx1, SSEx2 both showed no significant changes of the expression of PPARδ reporter gene activities in C2C12 skeletal muscle cells. 4. SSEx1 increased the modulation of mitochondrial MCAD mRNA expression (p<0.05) significantly in NMu2Li liver cell lines. 5. SSEx1, SSEx2 both increased the modulation of mitochondrial MCAD mRNA expression (p<0.05) significantly in C2C12 skeletal muscle cells. Conclusions : These results show the SSEx1, SSEx2 can be used as therapeutic agent for metabolic syndrome and it's molecular mechanisms of PPAR more contribute to the activation of PPARα then PPARδ reporter gene activities and it's total RNA more contribute to the modulation of mitochondrial MCAD then VLCAD mRNA expression.

keywords
Sopungsungi-won(Shufengshunqiyuan) (SSEx1, SSEx2), PPAR<TEX>${\alpha}$</TEX>, PPAR<TEX>${\delta}$</TEX>, MCAD, VLCAD, metabolic syndrome

동의신경정신과학회지